Fragment 176-191 peptide, also known as hGH Fragment 176-191 or modified AOD-9604, has been hypothesized by researchers based on experiments conducted in the laboratory to increase a state of metabolic action and energy expenditure, in addition to perhaps aiding in the elevation of IGF-1 levels.
This hypothesis is based on the working research hypothesis that this peptide exhibits the potential to increase IGF-1 levels.
Growth hormone, often known as hGH, is a hormone that is thought to have a significant role in the process of development and growth.
In addition, hGH is an important component that appears to play a vital role in regulating various metabolic processes.
These processes include the development of a hyperglycemic state as well as the maintenance of an optimal metabolic rate.
Researchers have developed several synthetic peptides to compensate for deficiencies in growth hormone levels (hGH).
The 191 amino acids that comprise growth hormone may be condensed into these synthetic peptides.
Fragment 176-191 is the name of one of these synthetic hGH peptides, and it has been the focus of a significant amount of study in the context of weight management in animal test models.
An Overview of the Fragment 176-191 Peptide
As suggested by several studies, Fragment 176-191 is a synthetic peptide that may potentially carry out the same tasks as a growth hormone (hGH).
Research suggests that the peptide Fragment 176-191, sometimes called Frag 176-191, may stimulate the anterior pituitary gland.
In turn, this may quicken the speed at which the metabolism operates and duplicate additional tasks comparable to those that hGH performs.
Researchers have reason to speculate that the peptide may be responsible for accelerated growth and development due to the above-mentioned reasons.
In addition, a recombinant growth hormone called somatotropin was manufactured to link with the growth hormone receptors in several different sites, the liver being the most prominent of these.
The production of insulin-like growth factors, also known as IGF-1 and IGF-2, is triggered as soon as the recombinant growth hormone contacts the receptors.
Scientists have a working hypothesis that higher IGF factors caused by peptides may be responsible for promoting glucose homeostasis and a high metabolism of carbs and lipids.
Regarding the peptide, the following is a summary of the key areas of attention that researchers have hypothesized:
- Possible quickening of the rate at which cells divide and multiply
- The potential for a speeding up of the metabolic process
- A potential for an impaired responsiveness to insulin
- Possible abilities to mend damaged tissue
Peptide Deficiency and the Lack of Growth Hormone in Fragment 176-191
The following are some of the symptoms that are often associated with growth hormone deficiency (GHD):
- Sustained growth retardation
- Little to no weight fluctuation
- Aging of the bones occurs more quickly
During five scientific investigations over the last several years, the synthetic peptide has been studied to determine any impact and potential mechanism of action.
Each study had its own set of conditions, such as subjects of shorter height and length than the average control measurements, satisfying a set of factors regarding bone age and exhibition of rapid growth.
Only the models capable of satisfying these prerequisites were scrutinized during the study.
The outcomes of the tests suggested that the peptide may have increased the likelihood of the models increasing in size and length.
Fragment 176-191 Peptide and Glycogen Metabolism
Fragment 176-191 was one of several synthetic hGH peptides presented to rats with normal functioning as part of a study to investigate the possible impact of the substance on glycogen metabolism.
The rats were also given other synthetic hGH peptides.
It was hypothesized that the peptide might cause a little elevation in the levels of glucose and lactate in the blood, in addition to a potential for a slight reduction in the proportion of glycogen synthase found in muscle, adipose tissue, and the liver.
It was speculated that the peptide’s apparent primary potential brought about this impact: changing the enzymes from their active state to an inactive one.
It was suggested that this function existed even though the synthase levels seemed unaltered.
Fragment 176-191 Peptide and Diabetic Ulcerations
For this experimental study, 10 research models of diabetic foot ulcers (DFU) were used. These subjects were all exhibitors of type I or type II diabetes.
The models were divided into two groups using a random selection process: the control group was given alginate dressing.
In contrast, the experimental group was given the alginate dressing and the rhGH Fragment 176-191 peptide.
The experimental group was used as the reference point for evaluating the control group’s results. There was no consensus among the researchers about how they felt about the findings of this study.
It is unclear how the peptide might affect DFU regarding its underlying mechanism.
The researchers have hypothesized three separate mechanisms: first, the stimulation of cell proliferation and cell growth; second, the immunomodulatory capacities; and third, angiogenesis.
The study yielded no clear answers or conclusions due to its findings.
The utilization of Core Peptides is limited to those of research and educational institutions, and it is also the subject of ongoing scientific investigation. See the whole selection of Core Peptides’ research peptides on their website.
This company is an authoritative source for peptides used in scientific research. It is important to remember that sales are only allowed to be made to active scientists.
The material provided in this article is not intended to serve as medical or research guidance in any way and should only be used for informational purposes only.
[i] Brinkman JE, Tariq MĂ, Leavitt L, et al. Physiology, Growth Hormone. [Updated 2021 May 7]. În: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. https://www.ncbi.nlm.nih.gov/books/NBK482141/
[ii] National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 16131230, Somatotropin (176-191). Retrieved June 21, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Somatotropin-_176-191
[iii] Reh, C. S., & Geffner, M. E. (2010). Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clinical pharmacology: advances and applications, 2, 111–122. https://pubmed.ncbi.nlm.nih.gov/22291494/
[iv] G.Y.W. Ma et al., The mechanism of the hyperglycaemic action of synthetic peptides related to the C-terminal sequence of human growth hormone, Biochimica et Biophysica Acta (BBA) – General Subjects, Volume 716, Issue 3, 1982, Pages 400-409, ISSN 0304-4165, https://doi.org/10.1016/0304-4165(82)90033-2